[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Impulse Dynamics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":142},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,57,89,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100444229","assessment-of-ccm-in-hf-with-higher-ejection-fraction-100444229",false,"NCT05064709","Assessment of CCM in HF With Higher Ejection Fraction","Assessment of Implantable CCM in the Heart Failure Group With Higher Ejection Fraction","AIM HIGHer","Inclusion Criteria:\n\n1. Signed and dated informed consent form;\n2. Male or non-pregnant female, 18 years or older;\n3. Diagnosed with symptomatic heart failure;\n4. LVEF ≥40 and ≤70% (as assessed by site echo);\n5. A. Heart failure hospitalization within 12 months prior to study consent OR an urgent heart failure visit requiring IV therapy within 6 months prior to study consent OR B. If there is no heart failure hospitalization within 12 months prior to study consent OR an urgent heart failure visit requiring IV therapy within 6 months prior to study consent, an elevated BMI-adjusted natriuretic peptide value must be achieved (Refer to Table 1 in Section 9.2.6)\n6. Subjects must meet one of the following conditions:\n\n   * Have stable, scheduled oral loop diuretic treatment (not just PRN) for a minimum of 30 days before providing study consent unless there is a documented allergy or intolerance.\n   * Eligibility for enrollment is maintained for patients on an SGLT2 inhibitor without prescribed concurrent standing loop diuretic therapy if investigators provide instructions for a flexible PRN diuretic regimen (deemed appropriate by the clinician in response to symptoms or weight gain) Note: Stable is defined as no more than a 100% increase or 50% decrease in dose within the last 30 days. A one-time hold of diuretic dosing for 24 hours during the 30-day period is allowed and not an exclusionary event.\n\nExclusion Criteria:\n\n1. Resting ventricular rate \\\u003C50 or \\>110 bpm;\n2. Resting systolic blood pressure \\\u003C100 or ≥160 mmHg;\n3. BMI greater than 46\n4. Any severe valvular stenotic disease or any severe valvular regurgitation;\n5. Mechanical tricuspid valve;\n6. Complex congenital heart disease;\n7. Exercise tolerance limited by a condition other than heart failure that, in the opinion of the investigator, contributes significantly to the primary symptoms of shortness of breath and\u002For exercise intolerance;\n8. Unable to walk at least 100 meters or walks more than 450 meters during a 6MWT;\n9. A KCCQ CCS score higher than 85;\n10. Hypertrophic, infiltrative\u002Frestrictive or inflammatory cardiomyopathy;\n11. Unstable angina pectoris within 30 days prior to study consent;\n12. Acute, decompensated heart failure requiring IV therapy or ultrafiltration within 30 days prior to consent, in the hospital or an outpatient setting;\n13. Receiving cardiac resynchronization therapy (CRT); NOTE: Subjects with active\u002Fongoing cardiac resynchronization therapy (CRT) implanted more than one year ago are eligible for inclusion if they are currently classified as NYHA class III or higher.\n14. Scheduled for a cardiac surgery or a percutaneous cardiac intervention (PCI) or have undergone cardiac surgery within 90 days or a PCI procedure within 30 days prior to study consent;\n15. Myocardial infarction within 90 days prior to study consent;\n16. Prior heart transplant or ventricular assist device;\n17. Planning to become pregnant during the study;\n18. Dialysis (permanent) or GFR \\\u003C15 ml\u002Fmin\u002F1.73m2;\n19. Participating in another investigational drug or device study that may interfere with the interpretation of study data;\n20. Currently undergoing active chemotherapeutic and\u002For radiation treatment for cancer or has a history of chemotherapy during the 2-year period prior to study consent;\n21. Expected lifespan of less than 18 months from time of study consent;\n22. Unable to follow through study protocol for any reasons in the investigator's judgement.","ALL","18 Years",{"count":20,"type":21},1500,"ESTIMATED","INTERVENTIONAL",[24],"NA","The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.",[27,28,29,30,31],"Heart Failure","Heart Failure With Preserved Ejection Fraction","Heart Failure With Mid Range Ejection Fraction","Heart Failure With Moderately Reduced Ejection Fraction","Diastolic Heart Failure",[33,34,35,36,37,38,39,40,41,42,43],"HFpEF","Heart failure","CCM","CCM therapy","cardiac contractility modulation","symptomatic heart failure","left ventricular ejection fraction","LVEF","Optimizer","Optimizer Smart Mini","Quality of Life","RECRUITING","2026-06-24",{"date":47,"type":48},"2026-06-26","ACTUAL",{"date":50,"type":48},"2022-02-03",{"date":52,"type":21},"2029-02-01",{"name":54,"class":55},"Impulse Dynamics","INDUSTRY",105,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":65,"targetDuration":67,"studyType":68,"phases":4,"briefSummary":69,"conditions":70,"keywords":71,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},"100601625","ccm-open-hf-registry-100601625","NCT07112924","CCM OPEN HF Registry","CCM Technologies OPEN HF Registry: Observational Patient EvaluatioN of CCM® Therapy for Heart Failure","CCM OPEN HF","Inclusion Criteria:\n\n* Patients who have \u002Fwill be implanted with Impulse Dynamics CCM technologies (e.g. CCM or CCM-D when available) as determined by investigators\n* Willing and able to provide informed consent, including for use of data for research purposes (e.g. publication, sub-studies\u002Fsub-analyses)\n\nExclusion Criteria:\n\n* Noncompliant patients (e.g. for follow-up visits, medication, etc.) as determined by investigators.\n* Subjects with a mechanical tricuspid valve",{"count":66,"type":21},5500,"5 Years","OBSERVATIONAL","The registry has been designed to evaluate the long-term safety and efficacy of CCM therapy in a real-world setting.",[27],[27,35,41,72,73,74,75,76,77,78,79],"Implantable Pulse Generator","FDA Approved","Heart Failure Hospitalization","Ischemic vs non-ischemic","CRT non-responders","Patients with concomitant devices","Patients with wide, intermediate, narrow QRS","Patients with cardiac amyloidosis","2026-04-20",{"date":82,"type":48},"2026-04-23",{"date":84,"type":48},"2025-11-01",{"date":86,"type":21},"2036-08-01",{"name":54,"class":55},28,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":99,"conditions":100,"keywords":103,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},"100609018","propensity-matched-study-of-cardiac-contractility-modulation-therapy-in-heart-failure-100609018","NCT07209098","Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart Failure","Broaden Accessibility of Breakthrough Treatment for Heart Failure: A Prospective, Propensity-Matched CED to Access the Impact of Cardiac Contractility Modulation Therapy (CCM)","BRIGHTEN-HF","Inclusion Criteria\n\n1. Continuous representation in the database in the year prior to index.\n2. Age 18 or older will be enrolled in either the treatment or control arm of the study.\n3. NYHA III heart failure,\n4. Not receiving CRT\n5. EF 25 - 45%, inclusive.\n6. Remain symptomatic despite at least 3 months of optimized guideline-directed medical therapy (GDMT) as determined by the heart team prior to CCM implantation.\n\nExclusion Criteria\n\n1. Subject has had a prior heart transplant\n2. Subject with mechanical tricuspid valve.\n3. Subject has a left ventricular assist device (LVAD).",{"count":98,"type":21},4200,"The purpose of this prospective, multi-center, propensity-matched coverage with evidence development (CED) study is to assess the impact of cardiac contractility modulation (CCM) on mortality and heart failure hospitalizations in Medicare-eligible patients with heart failure who meet indications for CCM.",[101,102],"Heart Failure and Reduced Ejection Fraction","NYHA Class III Heart Failure",[34,104,105,35,106,107,108,109,110],"Reduced ejection fraction","Cardiac Contractility Modulation","NYHA III","Propensity Score Matching","All-Cause Mortality","Heart Failure Hospitalizations","CED","2026-03-23",{"date":113,"type":48},"2026-03-24",{"date":115,"type":48},"2025-11-18",{"date":117,"type":21},"2031-04",{"name":54,"class":55},1,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":129,"conditions":130,"keywords":131,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":141},"100560687","ccm-and-implementation-of-guideline-directed-medical-therapy-in-patients-with-heart-failure-fix-gdmt-hf-100560687","NCT06580392","CCM and Implementation of Guideline-Directed Medical Therapy in Patients With Heart Failure (Fix-GDMT-HF)","Cardiac Contractility Modulation (CCM) and Implementation of Guideline-Directed Medical Therapy in Patients With Heart Failure","Inclusion Criteria:\n\n1. Adults (≥18 years) diagnosed with symptomatic heart failure\n2. Patients with Heart failure with reduced Ejection Fraction (HFrEF) where the Ejection Fraction (EF) is ≤40%\n\n   \\- Historical LVEF assessed up to 6 months prior to consent by any modality can be used if available\n3. Patients can have an active concomitant CRT device already - implanted provided the following criteria:\n\n   * CRT device has been implanted \\>1 year\n   * Patients are functional class NYHA III-IV\n\nExclusion Criteria:\n\n1. Patients that are unlikely to adhere to medical therapy for reasons other than intolerance or contraindications.\n2. Patients with a QMS score \\>5\n3. eGFR \\\u003C15\n4. Patients with a concomitant CRT device that has already been implanted and deemed to be a responder\n5. Patients with class I indication for a concomitant CRT device\n6. Patients with significant comorbidities or conditions that may interfere with the study assessments\n7. Patients with contraindications to CCM therapy or unable to undergo implantation\n8. Severe stenotic valve disease",{"count":128,"type":21},200,"The primary objective of this study is to evaluate the impact of Cardiac Contractility Modulation (CCM) therapy on the initiation and up-titration of Guideline-Directed Medical Therapy (GDMT) in patients with heart failure (HF). This will be assessed by the change in Quad Medication Score (QMS) from baseline (pre-CCM) to 6-month following post-CCM device implant.",[27],[132],"Change in Quad medication score","2025-07-08",{"date":135,"type":48},"2025-07-11",{"date":137,"type":48},"2025-02-01",{"date":139,"type":21},"2027-12",{"name":54,"class":55},2,""]